Literature DB >> 2051906

Reversible cholestasis with bile duct injury following azathioprine therapy. A case report.

Y Horsmans1, J Rahier, A P Geubel.   

Abstract

A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy. Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts. Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities. It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2051906     DOI: 10.1111/j.1600-0676.1991.tb00497.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  5 in total

1.  Severe cholestasis due to azathioprine in Behcet's disease.

Authors:  Kadir Gisi; Murat Ispiroglu; Bulent Kantarceken; Hamide Sayar
Journal:  BMJ Case Rep       Date:  2019-03-31

2.  Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro.

Authors:  Chao Liu; Thomas Schreiter; Andrea Frilling; Uta Dahmen; Christoph E Broelsch; Guido Gerken; Ulrich Treichel
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

Review 3.  Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.

Authors:  Sarah Tischer; Robert J Fontana
Journal:  J Hepatol       Date:  2013-11-23       Impact factor: 25.083

Review 4.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

5.  Bile ductopenia following therapy with sulpiride.

Authors:  D Villari; F Rubino; F Corica; S Spinella; E Di Cesare; G Longo; G Raimondo
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.